Someone else has also since mentioned $JAKK to me - it's a (shitco) toy maker, similar to Character Group #CCT in the UK. CC's tweet mentions the refi, he has a point - I think there may be something here to play for, perhaps towards a double or so before the end of the year.
Company has cash of $80M + new debt of $99M (pink) repays difference on prior debt of $129M with cash on hand (green) so $50M cash + debt $99M
6,395 shares at $10.6, converts at $5.65 (purple) into $18.9M (blue) so + 3,345 shares = 9,740 / $103 cap & $20M prefs (grey) $172M EV
As you can see it's highly seasonal into Q3. Mgmt mentioned in the last (Q1) call that inventories are low. Typically they would be about $20M higher than here in Q2, so if we penalise the cash in the EV by that amount to account for inventory build we're at $192M
Giving a trailing EV/LTM EBITDA of x4.8 and looking for significantly increased profitability this year - and that against some easier comps
And JAKK doesn't seem too badly placed for the categories called out by the article above
And yes, they do have Raya too
If you assume they increase their revenues in line with the overall toy industry growth figure of +27% and do $51M (vs $40) in EBITDA then their current valuation comes out at 3.75x - even for a shitco, this is quite cheap. Hold the multiple at 4.8x and the shares are $16, up 50%
The measly rise in the shares since the refi announcement implies these savings being capitalised at 2-3x - again, that's perhaps on the low side. Half a turn more on the multiple and $51M EBITDA has shares at $18.6 vs today's mid $10
Estimates suggest $39M EBITDA for FY21, my guess would be that they're perhaps on the low side given the comments on the call and this point from the toynews article
Q1/21 revenues were up 26% but the estimates for the money making quarter are down 5%, seems a little incongruous to me.
#CCT in the UK at end April reported revs up 44% in the HY to Feb and already had this to say about the H2. UK isn't the US but with a refi barely priced in and a fair environment for toy sales, some sales growth and multiple expansion for $JAKK don't seem too unreasonable to me
• • •
Missing some Tweet in this thread? You can try to
force a refresh
On the Bridgestone side of things, the sensors monitor all aspects of super-large mining trucks' tire condition and provide geofencing and advanced capabilities for. Beyond likely cashflows the optionality here is to expand within the B'Stone range.
Unfortunately this involves banks, turnarounds and LendingClub $LC but I think something potentially quite interesting may be happening here, due to this acquisition:
When I mentioned to Munger and Buffett the other day that I was reading up on LendingClub this was the reaction - and they're not too wrong: LC is crap
However, the business model is a little different these days and if my guess is right, it may all end up becoming little more than a vestigial artifact, like Chamath's legs
Where things stand now is that it's no longer so much a P2P lender.
For a long time I thought computational drug modelling really had only one listed company: $SLP
Turns out maybe not: Physiomics #PYC could be a decent candidate for a comp.
Growth is inflecting, it has optionalities and thanks to AIM obscurity it's on a fwd EV/Sales of 6.5x
I first bought $SLP in April 2013. I mention this to make the point that was long before the current bubble in futuristic healthcare stocks, or before SaaS was a thing, this was already a punishingly expensive sector.
Here are the multiples you would've seen back then
SLP was pure software to model drug absorption, sold on licence. It had incredible margins but slow, steady growth. In 2013 it did $10M in revs and in the most recent like-for-like split, FY19, it did $20: ~+10% a year or so
This is again the idea: Pfizer wants to get a powder version of the Covid vaccine in order to avoid the cold-chain issues and expenses associated with the first-gen vaccine
- I am far, far out of my lane looking at this
- The comp lives in a bubble market
- This is 100% based on crude pattern recognition
- Market appears to value #RENE for other aspects, so
- This may not work even if the idea proves correct
So, #RENE may have what may be one of the Next Big Things: a platform for the cutting edge of genetic medicine - the comp lives off that alone.
In English, they use "exosomes" to try to get mRNA and CRISPR molecules past the blood-brain barrier into the brain. See below